Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study

Alsobhi, Enaam; Abrar, Mohammed Burhan; Abdelaal, M.; Alsaeed, Ahmed; Absi, Ahmed; Alzahrani, Zayed; El-Hemaidi, Ihab; Alshehri, Mohammed Ali; Warsi, Ashraf; Bayashoot, Safaa; Hashem, Heba; Merdad, Anas; Radi, Suhaib; Shiekhi, Hanadi; Al-Amri, Abdulfattah

doi:10.3109/10428194.2014.935365

Cited by 9 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our analysis, the PFS, and the percentage of those who are still receiving imatinib, were inferior to the previously published trials, including some studies in other developing countries [38,39]. These results could be attributed to small number of patients, retrospective nature of the study, and irregular intake of imatinib.…”

Section: Discussioncontrasting

confidence: 83%

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience

Edesa

Abdel-Malek

2015

Journal of the Egyptian National Cancer Institute

View full text Add to dashboard Cite

Duration of prior hydroxyurea had no impact on response or progression free survival, while patients regular on imatinib had statistically significant difference with respect to major molecular response, complete molecular response and progression free survival compared to those who had periods of drug interruption, thus we need more governmental support to supply the drug without interruption to improve the outcome of therapy.

show abstract

Section: Discussioncontrasting

confidence: 83%

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience

Edesa

Abdel-Malek

2015

Journal of the Egyptian National Cancer Institute

View full text Add to dashboard Cite

show abstract

“…Survival advantages of TKIs in patients with MPNs have been proven in previous studies. [40][41][42] However, this study affirmed that this advantage is gained when TKIs are used as first line and lost or reduced when they are used as second line drugs whether right after HU or even other TKI.…”

Section: Discussionmentioning

confidence: 61%

Treatment with Tyrosine Kinase Inhibitors in Chronic Myeloproliferative Neoplasms: Pros and Cons

Khaled¹

2016

AJIM

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) are a group of hematological disorders characterized by proliferation of one or more than one myeloid lineage. Genetically they express single or multiple mutations of the Janus tyrosine kinase receptors. Advances in understanding molecular and cytogenetic pathophysiology of MPNs led to further identification of different mutations rather than the classical break point cluster region Abelson (BCR-ABL). Although the onset of disease in all MPNs is insidious and may be asymptomatic, also MPNs run a slowly progressive course however they carry the potential of blastic transformation. Furthermore, peripheral blood leucocytosis, thrombocytosis or erythroctosis can lead to a wide array of fatal complications. Originally treatment of MPNs based on cytoreduction and supportive measures. Tyrosine kinase inhibitors (TKIs) are a group of anti-neoplastic drugs that specifically targeting malignant cells. Many studies proved the efficacy and safety of TKIs in management of patients with MPNs. This study was conducted to evaluate TKIs, pros and cons.

show abstract

“…Participants in this study were members of the Saudi population diagnosed with CML and treated at King Abdulaziz Medical City, Jeddah [ 16 ]. A total of 104 CML patients received 400 mg imatinib as the initial therapy.…”

Section: Methodsmentioning

confidence: 99%

Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib

Banjar

Alsobhi

2017

International Scholarly Research Notices

Self Cite

View full text Add to dashboard Cite

Inconsistency in prognostic scores occurs where two different risk categories are applied to the same chronic myeloid leukemia (CML) patient. This study evaluated common scoring systems for identifying risk groups based on patients' molecular responses to select the best prognostic score when conflict prognoses are obtained from patient profiles. We analyzed 104 patients diagnosed with CML and treated at King Abdulaziz Medical City, Saudi Arabia, who were monitored for major molecular response (achieving a BCR-ABL1 transcript level equal to or less than 0.1%) by Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR), and their risk profiles were identified using Sokal, Hasford, EUTOS, and ELTS scores based on the patients' clinical and hematological parameters at diagnosis. Our results found that the Hasford score outperformed other scores in identifying risk categories for conflict groups, with an accuracy of 63%.

show abstract

Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study

Cited by 9 publications

References 28 publications

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience

Treatment with Tyrosine Kinase Inhibitors in Chronic Myeloproliferative Neoplasms: Pros and Cons

Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib

Contact Info

Product

Resources

About